Holen Sie sich die Stockscreener-App
0.6349
18.32%
-0.1429
Schlusskurs vom Vortag:
$0.7778
Offen:
$0.7102
24-Stunden-Volumen:
2.89M
Relative Volume:
2.51
Marktkapitalisierung:
$11.14M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.60M
KGV:
-0.7134
EPS:
-0.89
Netto-Cashflow:
$-23.48M
1W Leistung:
-20.88%
1M Leistung:
-78.17%
6M Leistung:
-84.31%
1J Leistung:
-93.06%
1-Tages-Spanne:
$0.61
$0.7444
1-Wochen-Bereich:
$0.61
$0.8099
52-Wochen-Spanne:
$0.61
$29.40
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Firmenname
Briacell Therapeutics Corp
Sektor
Branche
Telefon
(604) 921-1810
Adresse
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Vergleichen Sie BCTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
0.6349 | 13.65M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.84 | 96.11B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
553.06 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.42 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
671.74 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.48 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Aktie (BCTX) Neueste Nachrichten
BriaCell Announces Share Consolidation to Maintain Nasdaq Compliance - TipRanks
BriaCell Sets August 25 for Major 10:1 Share Consolidation: What Shareholders Must Know - Stock Titan
BriaCell Announces Proposed Effective Date of Share Consolidation - GlobeNewswire
My Honest Opinion of Energy Transfer Stock - The Globe and Mail
Simon Property Reports Strong Q2 2025 Financial Results - The Globe and Mail
What institutional investors are buying BriaCell Therapeutics Corp. Equity Warrant stockUnlock powerful stock screening techniques - Jammu Links News
How does BriaCell Therapeutics Corp. compare to its industry peersDiscover high-impact investment opportunities - Jammu Links News
How does BriaCell Therapeutics Corp. Equity Warrant generate profit in a changing economySuperior risk-adjusted returns - Jammu Links News
(BCT) Technical Pivots with Risk Controls (BCT:CA) - news.stocktradersdaily.com
What institutional investors are buying BriaCell Therapeutics Corp. stockDiscover the next big stock winners - Jammu Links News
What makes BriaCell Therapeutics Corp. stock price move sharplyCapitalize on emerging trends for profits - Jammu Links News
How volatile is BriaCell Therapeutics Corp. Equity Warrant stock compared to the marketMassive portfolio appreciation - Jammu Links News
BriaCell Therapeutics Corp. Equity Warrant Stock Analysis and ForecastGet daily updates on promising stocks - Jammu Links News
How does BriaCell Therapeutics Corp. Equity Warrant compare to its industry peersHigh-octane gains - Jammu Links News
What makes BriaCell Therapeutics Corp. Equity Warrant stock price move sharplyUnlock powerful market insights for success - Jammu Links News
What drives BriaCell Therapeutics Corp. Equity Warrant stock priceMaximize returns with data-driven strategies - Jammu Links News
What is the dividend policy of BriaCell Therapeutics Corp. Equity Warrant stockMaximize gains with expert analysis - Jammu Links News
Published on: 2025-08-03 12:02:14 - Jammu Links News
What is the risk reward ratio of investing in BriaCell Therapeutics Corp. Equity Warrant stockAchieve consistent double-digit returns - Jammu Links News
Should I hold or sell BriaCell Therapeutics Corp. Equity Warrant stock in 2025Tremendous return rates - Jammu Links News
What catalysts could drive BriaCell Therapeutics Corp. Equity Warrant stock higher in 2025Invest smarter with comprehensive market analysis - Jammu Links News
How does BriaCell Therapeutics Corp. generate profit in a changing economyProven strategies for superior portfolio growth - Jammu Links News
What catalysts could drive BriaCell Therapeutics Corp. stock higher in 2025Sky-high return potential - Jammu Links News
Is BriaCell Therapeutics Corp. Equity Warrant stock overvalued or undervaluedRapid portfolio appreciation - Jammu Links News
Is it the right time to buy BriaCell Therapeutics Corp. Equity Warrant stockDouble-digit growth - Jammu Links News
Off-market insider buying at Atico Mining (ATY) - The Globe and Mail
BriaCell Therapeutics Corp. Recovery Hinges on Volume BreakoutWeekly Setup With 3x Return Potential Published - metal.it
Is BriaCell Therapeutics Corp. a growth stock or a value stockPre Market Review For Consistent Profits - Jammu Links News
BriaCell Expands Phase 3 Breast Cancer Study with UCLA Health Partnership - TipRanks
UCLA Health joins BriaCell’s phase 3 breast cancer study By Investing.com - Investing.com Nigeria
UCLA Health joins BriaCell’s phase 3 breast cancer study - Investing.com
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study - GlobeNewswire
FDA Fast-Tracked: UCLA Health to Test BriaCell's Novel Breast Cancer Immunotherapy in Pivotal Phase 3 Trial - Stock Titan
Foraco International reports Q2 2025 - The Globe and Mail
WALSH PURE SPREADER -Pure Hedge Division - The Globe and Mail
BriaCell granted New Zealand patent for cancer immunotherapy method By Investing.com - Investing.com South Africa
BriaCell granted New Zealand patent for cancer immunotherapy method - Investing.com
BriaCell Awarded New Zealand Patent for its Whole Cell Technology - GlobeNewswire
Why BriaCell Therapeutics Corp. Equity Warrant stock attracts strong analyst attentionInvestment Playbook for Growing Markets Shared - metal.it
BriaCell Secures New Zealand Patent for Cancer Immunotherapy - TipRanks
BriaCell Secures Game-Changing Cancer Immunotherapy Patent: Breakthrough in Personalized Treatment - Stock Titan
Published on: 2025-07-30 10:30:41 - metal.it
BriaCell Therapeutics Files Patent for Cancer Treatment Platform - AInvest
Is BriaCell Therapeutics Corp. Equity Warrant a Top Dividend Stock to Watch in 2025 - metal.it
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents - GlobeNewswire
BriaCell Therapeutics Corp. Recovery Linked to Earnings SurpriseDaily Momentum Screener With Alerts Launched - metal.it
Published on: 2025-07-29 17:12:14 - metal.it
BriaCell Therapeutics Corp. Equity Warrant Recovers — But Is It SustainableReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
BriaCell’s BriaPro Files Patent for Innovative Cancer Treatment Platform - TipRanks
Revolutionary Cancer Treatment: BriaCell's New Platform Targets 5 Major Cancer Types Simultaneously - Stock Titan
Why did BCTX report zero EPS for Q3 2023? - AInvest
Finanzdaten der Briacell Therapeutics Corp-Aktie (BCTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):